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ABSTRACT

Effects of Diabetic State and Gender on Pro-Inflammatory Cytokine Secretion by
Human Macrophages Infected with Burkholderia pseudomallei

Annette J. Blam
Department of Microbiology and Molecular Biology
Master of Science

Burkholderia pseudomallei is a gram-negative opportunistic soil pathogen that causes the lifethreatening disease melioidosis. It is endemic in Northern Australia and Southeast Asia but can
be found throughout many other regions in the world. Diabetes mellitus is a predisposing risk
factor for infection with this organism and it has been demonstrated that diabetic males are
particularly susceptible to severe infection. Previous research suggested that monocytes isolated
from the whole blood of diabetic males demonstrated a decreased ability to produce the
proinflammatory cytokines IL-1β and IL-8. We hypothesized that monocyte-derived
macrophages from diabetic males would also secrete lower levels of pro-inflammatory cytokines
and that this difference between gender and diabetic state would be more pronounced compared
to those seen previously with monocytes. Twenty volunteer with type I diabetes mellitus (ten
males and ten females), along with twenty healthy age- and gender-matched controls donated
blood for this study. Monocytes were collected from whole blood and allowed to differentiate
into macrophages with the use of human recombinant granulocyte-macrophage colonystimulating factor (GM-CSF). Macrophages were then divided into groups and infected with B.
pseudomallei, B. thailandensis (a closely related by non-pathogenic bacterium that inhabits
similar niches), and E. coli. An uninfected control was used as well. At six hours post-infection,
mRNA was collected from all cells and qPCR was performed to determine cytokine expression
levels. All mRNA values collected from cells which had been infected with bacterial agents
were normalized against the corresponding concentrations of mRNA from mock-infected cells.
Mean log fold increases in both IL-1β and IL-8 were computed and compared. Preliminary
testing showed decreased levels of both IL-1β and IL-8 from B. pseudomallei-infected
macrophages isolated from a diabetic male compared to the healthy, age-matched male control.
Surprisingly, results from all forty donors demonstrated that gender and diabetic state were not
significant factors in the proinflammatory responses of macrophages infected with B.
pseudomallei, although further testing is needed to determine if these results were influenced by
experimental parameters.
Keywords: Burkholderia pseudomallei, melioidosis, diabetes mellitus, proinflammatory cytokine

ACKNOWLEDGEMENTS

I am so truly thankful to everyone that helped me during these last two years. Thanks to
my family and friends for being there for me, especially my mom, who has spent countless hours
listening to me on the phone. None of this would have been possible without the constant
support from my parents and for that I am so grateful.
I sincerely thank Dr. Robison for all of the support he has given me over the last few
years and for always taking the time to explain anything and everything to me. I could not have
picked a better laboratory to study in.
Thanks to Dr. O’Neill, who has also always been there for me when I needed help and for
always being there to make me laugh. Thanks to Dr. Wilson for his mentorship and for always
making me think critically (even though I frequently did not want to).
I would also like to thank everyone that donated blood for me, often free of charge—
which includes most of the people in the lab (particularly Teri Bills and Jordan Meyers): thank
you for being so great about letting me stick you with needles on a weekly basis. Thanks to
Tyler and Matt for basically being on-call when I needed a phlebotomist. And thank you to
Emily Moore—I would not have survived without you.

Table of Contents
Table of Contents ....................................................................................................................... v
List of Tables ...........................................................................................................................vii
List of Figures ........................................................................................................................ viii
Introduction ............................................................................................................................... 1
Epidemiology ......................................................................................................................... 2
Melioidosis ............................................................................................................................. 2
Clinical Manifestations ........................................................................................................... 4
Host Immune Response .......................................................................................................... 6
Cytokines ............................................................................................................................... 8
Putative Virulence Factors ......................................................................................................... 9
Epithelial Attachment ............................................................................................................. 9
Intracellular Survival and Spread ............................................................................................ 9
Capsular Polysaccharides ...................................................................................................... 10
Biofilm Formation ................................................................................................................ 11
Lipopolysaccharide ............................................................................................................... 12
O-Antigen ............................................................................................................................. 12
Flagella ................................................................................................................................. 13
Pili ........................................................................................................................................ 13
Quorum-Sensing ................................................................................................................... 14
Type III Secretion System ..................................................................................................... 15
Type VI Secretion System .................................................................................................... 16
Siderophore .......................................................................................................................... 16
Protease ................................................................................................................................ 17
Homology ................................................................................................................................ 17
Taxonomy ............................................................................................................................ 17
B. thailandensis .................................................................................................................... 18
Key Differences .................................................................................................................... 18
B. mallei ............................................................................................................................... 19
Other Species ........................................................................................................................ 19
iv

Animal Models ........................................................................................................................ 20
Vaccination .............................................................................................................................. 21
Diabetes ................................................................................................................................... 22
Current Study ........................................................................................................................... 23
Materials and Methods ............................................................................................................. 24
Results ..................................................................................................................................... 29
Discussion ................................................................................................................................ 33
Reference ................................................................................................................................. 51

v

List of Tables
Table 1 Sequences of primers and probes used for qPCR .......................................................... 40
Table 2 Ages of blood donors ..................................................................................................... 41
Table 3 HbA1c levels of diabetic donors...................................................................................... 42

vi

List of Figures
Figure 1 Variable colony morphology of B. pseudomallei in pure culture ................................. 43
Figure 2 Fluorescence microscopy of human macrophages ........................................................ 44
Figure 3 Log fold increase in expression of IL-1β and IL-8 ........................................................ 45
Figure 4 Effect of kanamycin on mRNA production ................................................................... 46
Figure 5 Diabetic vs. healthy control log fold expression of cytokines ....................................... 47
Figure 6 Log fold expression of cytokines, male and female; ELISA ......................................... 48
Figure 7 Mean log fold increases in IL-1β and IL-8, whole study ............................................... 49
Figure 8 Mean log fold increases in IL-1β and IL-8 depending on infectious organism ............. 50

vii

Introduction
Burkholderia pseudomallei is a gram-negative environmental saprophyte. It is nonspore-forming, aerobic, and motile by way of a polar tuft of two to four flagella (26). B.
pseudomallei has a large genome divided between two chromosomes that are 4.07 Mb and 3.17
Mb in size (a total of 7.24 Mb) (101). The larger of the two chromosomes contains the housekeeping genes, such as those needed for cellular growth and metabolism including gene clusters
encoding the lipopolysaccharide and capsular polysaccharide, while the smaller of the two
chromosomes contains accessory genes; those needed for adaptations and survival under harsh
conditions, including those encoding the putative type III secretion system (77). It is believed
that the large size of B. pseudomallei’s genome accounts for the organism’s adaptability and
versatility (31). The genome has a G+C content of 68%, which is relatively high compared to
many other bacteria (101). B. pseudomallei produces many cell-associated and secreted
substances associated with virulence, including hemolysin, phospholipase C, proteases, type III
secretion systems, a siderophore, and other factors (53). It is resistant to damage from
complement, lysosomal defensins, and cationic peptides (101). B. pseudomallei grows
aerobically on most agar media and visible colonies are produced in about 24 hours at 37 C, but
colony morphology can be highly variable: with morphologies ranging from smooth to the more
common rough type, and sometimes mucoid (84). A Gram stain of this organism shows bipolar
staining. It is oxidase positive and can reliably be identified by its biochemical profile with kitbased systems (101). B. pseudomallei is currently listed by the Center for Disease Control and
Prevention (CDC) as a category B select agent because of its high potential for bioweaponry and
its extensive antibiotic resistance. The United States Department of Agriculture (USDA) also
has this organism listed as a select agent, due to its significant animal pathogenicity (108).
1

Epidemiology
B. pseudomallei is readily cultured from the soil, water, and importantly, rice paddies in
endemic areas including South East Asia, northeast Thailand, and northern Australia. It can also
be found throughout the tropics and subtropics, specifically countries that are located within 20
north and 20 south of the equator (74). Sporadic cases have been described in Mexico, Papua
New Guinea, the Philippines, South America and Africa (44). It is rare in North America. Most
of the few cases that have been reported are due to either a laboratory-acquired infection or
involve an individual who has traveled to an endemic area. In Taiwan, it was found that B.
pseudomallei could be cultured from depths of 300-600 mm under crop-covered fields (17).
There has been little evidence found to support the idea of natural vector-borne transmission of
B. pseudomallei (94). While B. pseudomallei is associated with many plant species, a specific,
natural niche for this organism remains to be identified (24).

Melioidosis
Melioidosis is the infectious disease caused by B. pseudomallei. It was first described in
1911 by pathologist Alfred Whitmore and his assistant C. S. Krishnaswami in Rangoon, Burma
(19). Septicemic melioidosis accounts for approximately one-fifth of all community-acquired
septicemias in northeast Thailand. In rice-farming communities, 80% of children have acquired
anti-B. pseudomallei antibodies by the time they reach five years of age, and while most of the
population in endemic areas have antibodies against B. pseudomallei, these antibodies have not
been shown to be protective (42, 101). Based on indirect hemagglutination assays, 80% of the
population in endemic areas have been exposed to this organism without manifesting clinical
symptoms (89). Also, in northeast Thailand, the vast majority of melioidosis cases occur in rice
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farmers and their families (64). In Singapore, melioidosis accounts for 7% of communityacquired pneumonias (101). In Northern Territory, Australia, there was a calculated mean
annual incidence of 19.6 per 100,000 people in 2004 (25). Not only are humans susceptible to
infection with B. pseudomallei, but many animals are as well. The list of organisms susceptible
to infection includes nematodes, amoeba, rodents, cats, dogs, swine, camels, horses, sheep, goats,
kangaroos, koalas, deer, alpacas, sea mammals (particularly dolphins), and large primates—
most notably highland gorillas (19, 21, 33, 46, 49, 88). Host body temperature does not appear
to be a factor in infection as this organism has also been reported to infect fish, snakes, and
crocodiles (90).
Humans are most often infected by cutaneous inoculation or inhalation, and less often
through ingestion, although transmission via sexual contact and birth have been reported (101).
Inoculation of environmental organisms into minor cuts or abrasions is also thought to be an
important route of infection. Melioidosis primarily affects those who come in contact with
contaminated soil and water and is a disease that is associated with rainy seasons. Heavy rain
fall may bring the bacterium to the surface and then aerosolize it from the soil and stagnant
water. Near drowning victims in endemic areas are highly susceptible to a pneumonic form of
melioidosis, presumably due to inhalation of a large inoculum from contaminated water. In
Thailand, exposure frequently occurs during rice farming since rice farmers often sustain many
minor cuts and abrasions while working in the rice paddies.
There are several predisposing conditions to infection by B. pseudomallei: diabetes
mellitus, renal disease, thalassaemia, alcoholism, cirrhosis, and immunosuppression are a few.
Patients with diabetes mellitus are particularly susceptible to melioidosis. About 60% of
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melioidosis cases in Thailand have pre-existing or newly diagnosed diabetes, usually with
indication of poor blood glucose control before infection occurred (16).
Pulmonary melioidosis was more common in U.S. soldiers working as helicopter
crewman in Vietnam and it was thought that this was because the rotor blades of the helicopter
dispersed B. pseudomallei into the air from the soil and the bacteria were then inhaled by the
soldiers. These observations are supported by the low rate of melioidosis seen in Japanese troops
that returned from South East Asia after World War II, who did not use helicopters (2). B.
pseudomallei is known to have a long latency period and a high rate of reactivity, with a 6-13%
chance of relapse among patients (1, 55). A report of reactivated melioidosis in a World War II
veteran 62 years after exposure has been documented (107). Reactivation is usually concurrent
with an immunocompromised state, often triggered by an infection or injury (44). Because of
the organism’s ability to sequester itself in the host and then reactivate much later in the host’s
life, the disease it causes has earned the name “Vietnam Time Bomb” (101). This organism has
been show to be able to survive in triple distilled water for more than three years (104).

Clinical Manifestaions
Clinical manifestations of melioidosis are highly variable and none are disease specific,
leading to frequent misdiagnosis. Symptoms can range from a chronic debilitating localized
infection to an acute fulminant septicemia. Other presentations can include soft tissue or skin
abscesses, peritonitis, genitourinary infections or neurological presentations (73, 101). Acute
infections can be divided into the pulmonary and septicemic forms, and either of these left
untreated can be fatal in a few days. The overall mortality for adult patients in Thailand is 50%,
while in Australia it is 20% (19, 101, 102). Most of the patients seeking therapy are septicemic,
and show no obvious infected wounds. The lung is most commonly infected, but abscess
4

formation in the spleen, liver, skeletal muscle, and prostate are also frequently seen (101).
Localized abscess formation, soft tissue infection, and asymptomatic disease with seroconversion
are common (43). In Thailand, children with melioidosis often present with acute suppurative
parotitis (fever with pain, and swelling over the parotid gland). This is more common in
Thailand (15%) than in northern Australia (4%), while presentation as brainstem encephalitis or
flaccid paraparesis is more common in Australia (4%) than in southeast Asia (0.2%) (101). The
most common misdiagnosis for pulmonary melioidosis is tuberculosis, as the manifestations are
quite similar (97). The incidence of melioidosis may be higher than current data implies because
melioidosis is difficult to diagnose. While melioidosis is more commonly seen in males in
endemic areas, studies have shown that there is higher seropositivity among females (50).
Diagnosis can be ascertained in many ways. B. pseudomallei is readily cultured from
infected sites and blood. Splenic abscesses are less commonly seen with other bacterial
infections, and in endemic areas, are more likely to occur than liver abscesses; especially since in
northeast Thailand, 95% of splenic abscesses are caused by B. pseudomallei (101). Culturing
from clinical samples is currently considered the “gold standard” in diagnosis (60). Serology is
not used for diagnosis due to the delayed seroconversion and the high seropositivity in endemic
regions (60).
Treatment of B. pseudomallei infections can prove difficult due to many factors: the
bacterium is intrinsically resistant to many antibiotics, there is a long latency period, and
predisposing conditions often contribute to infection. Because clinical manifestations are highly
variable, correct diagnoses may not always be timely, and this can also impede treatment. B.
pseudomallei is susceptible to chloramphenicol, the tetracyclines, trimethoprimsulfamethoxazole, amoxicillin-clavulanate, third generation cephalosporins, and carbapenems.
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The current, most effective treatment consists of either a combination of four antibiotics
(chloramphenicol, doxycycline, and trimethoprim-sulfamethoxazole), or of ceftazidime alone.
This treatment is carried out for 20 weeks, with a relapse rate of 10% (101). Resistance to
penicillins, macrolides, aminoglycosides, rifamycins, first and second generation cephalosporins,
and colistin is an intrinsic property of the bacterium (101).

Host Immune Response
The underlying immunological mechanisms responsible for the variable clinical
manifestations in melioidosis are still unclear. The ability of B. pseudomallei to infect, survive
in, and replicate inside both phagocytic and non-phagocytic cells may play a role in the different
disease symptoms. Development of adaptive cell-mediated immune responses have been shown
both clinically and experimentally to be essential for host survival following infection with B.
pseudomallei. Individuals that are exposed to this organism but do not become ill, may
seroconvert and develop a strong cell-mediated immune response that may protect them from a
progressive infection (50).
In both mice and humans, IFN- γ is essential for early control of B. pseudomallei
infection (12). CD4+ T cells specific for B. pseudomallei secrete INF- γ following exposure to
the organism (89). For many intracellular pathogens, caspase-1 is crucial for host resistance.
Caspase-1 is a member of the inflammatory caspases and is involved in the maturation of IL-1β
and IL-18, which are both pro-inflammatory cytokines (12). In macrophages, caspase-1dependent mechanisms are factors in the control of intracellular replication of B. pseudomallei
(12). An important part of the host defense against infection with this organism is caspase-1dependent IL-18-mediated IFN- γ production (12). Human natural killer (NK) cells are also
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important producers of IFN- γ. In a study by Tippayawat, et al, it was shown that NK cells
provided 80% of the IFN- γ in the first few hours of infection (89).
Polymorphonuclear leukocytes (PMNL) are important in containing the initial infection
of B. pseudomallei as supported by the use of granulocyte-colony stimulating factor (G-CSF) in
patients with melioidosis septicemia; an increase in survival was shown with those receiving GCSF (25). Some studies, such as one by Egan, et al, have shown that B. pseudomallei is resistant
to destruction by PMNLs (30).
Killing by macrophages is an important component of the innate immune system. B.
pseudomallei stimulates macrophages weakly; this enables the organism to evade killing by these
phagocytes (67). The importance of macrophages in combating an infection with B.
pseudomallei has been demonstrated by Wikraiphat, et al, who, using dichloromethylene
biphosphonate-containing liposomes, depleted mice of their macrophages. When these mice
were infected with B. pseudomallei, they were more highly susceptible to active infection (103).
Macrophages use reactive oxygen intermediates (ROI) and reactive nitrogen intermediates (RNI)
to destroy intracellular bacteria. In vitro, it has been shown that B. pseudomallei is susceptible to
both ROI and RNI (16). Miyagi, et al, found that IFN-γ-activated macrophages use ROI- and
RNI-dependent killing mechanisms to prevent the growth of this organism intracellularly (61).
As it was also found that B. pseudomallei was able to multiply intracellularly within
unstimulated macrophages, stimulation to activate ROI and RNI may be important in the clearing
of this organism from within these phagocytes (61).
Classical activation of macrophages, such as activation by microbial products, leads to
type-1 macrophages (M-1), which produce proinflammatory cytokines. The production of these
cytokines can then, in turn, lead to an active immune response against the invading
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microorganism and promote cell-mediated immunity. Alternative activation of macrophages can
lead to the production of M-2 macrophages. These cells produce anti-inflammatory cytokines,
such as IL-10, and are poor antigen presenting cells in comparison with M-1’s. This leads to a
poor cell-mediated immune response. Verreck, et al, has demonstrated that the priming of
human blood monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF)
generates pro-inflammatory type-one macrophages (M-1) (98). GM-CSF is known to act on
monocytes, enhancing not only phagocytosis, but intracellular killing mechanisms as well (82).

Cytokines
A few key cytokines are specifically involved in the host response to an infection with B.
pseudomallei: IFN- γ, TNF-α, and IL-1β (70). Cytokines found to be increased in the serum of
patients suffering from melioidosis include IFN- γ, TNF-α, IL-6, IL-8, IL-18, IL-12 p40, IL-15,
IFN-γ-inducible protein 10, and monocyte IFN-γ-inducible protein (70). IFN- γ produced by
natural killer (NK) cells and CD8+ T cells is critical in host defense. Cells of the monocyte
lineage produce IL-1β, a strong pro-inflammatory cytokine, in response to many different
microbial products, including LPS. The increased levels of IL-1β seen in melioidosis patients
may be due to the proliferation of monocytes, as it has been reported that the LPS of B.
pseudomallei has strong mitogenic activity (70). Studies on macrophage cell lines demonstrated
a decrease in the production of TNF-α when these cells were stimulated with B. pseudomallei
LPS, and no inducible nitric oxide synthase (iNOS) was produced. Opposite effects were seen
when macrophages were stimulated with E. coli LPS, indicating that the LPS of B. pseudomallei
may be interrupting critical macrophage functions (70).
IL-8 is an important cytokine in host defenses against bacterial pathogens. It is a
powerful neutrophil chemoattractant and is involved in the trafficking of these immune cells
8

across the endothelium. This cytokine is secreted by activated macrophages, phagocytosing
neutrophils, endothelial cells, and fixed tissue cells. In a study done by Friedland, et al, it was
demonstrated that plasma concentrations of both IL-6 and IL-8 were a better predictor of patient
mortality than plasma concentrations of TNF-α in B. pseudomallei infections (34).

Putative Virulence Factors
Epithelial Attachment
It has been shown by Kanaphun and others that there is a relationship between
pharyngeal colonization by B. pseudomallei and pulmonary infection (40). This organism
expresses functional adhesins. Adhesins are surface molecules that mediate the attachment to
specific receptors present on the surface of a host cell. It has been shown by Gori, et al, using
thin layer chromatography, that B. pseudomallei binds to the asialoganglioside aGM1-aGM2
(40). The surface molecule on B. pseudomallei that mediates this attachment is still unknown,
however Pseudomonas aeruginosa, a closely related organism, mediates this same attachment
via type IV pili (40). A study done with a B. pseudomallei K96243 type IVA mutant strain
showed reduced adhesion to epithelial cell lines, providing evidence that perhaps B.
pseudomallei uses type IV pili to attach to host cells in a manner similar to that used by P.
aeruginosa (1). It has been shown that the level of attachment of B. pseudomallei is quite low
and that this may account for the need for greater bacterial loads in order to cause infection, and
why this organism is often an opportunistic pathogen (2).
Intracellular Survival and Spread
Intracellular pathogens have adopted many strategies to evade host defenses. This
includes invading non-professional phagocytes, escaping into the cytoplasm of host cells,
9

interfering with reactive oxygen intermediates, inhibition of fusion of the phagosome with the
lysosome, and resistance to cationic peptides and lysosomal contents (44). B. pseudomallei is
able to actively invade and multiply in both phagocytic and non-phagocytic cells. Initially after
cellular uptake, the bacteria can be seen in vacuoles and later in the cytoplasm, where they
replicate (1). Within B. pseudomallei-infected human macrophages, lysosome fusion is detected,
but to a small degree, and eventually the proliferation of bacteria that survived the fusion
overwhelms the macrophage. Once inside the cytoplasm, the organism can induce actin
rearrangement. This polymerization of host cell actin is initiated at one pole of the bacterium
leading to actin tail formation and actin-associated peripheral membrane protrusions (69). This
host cell actin utilization allows the bacterium to spread from cell to cell. The Arp2/3 complex is
involved in B. pseudomallei-induced actin polymerization much like the actin-based motility
seen in Listeria, Shigella, and the vaccinia virus (11). However, unlike either Shigella or
Vaccinia, activation of the Arp2/3 complex is N-WASP independent. Listeria monocytogenes
uses a surface protein, ActA, to activate Arp2/3. The ActA-like protein of B. pseudomallei
mimics WASP/Scar family proteins in that it activates and recruits Arp2/3 (11). Stevens, et al,
found that induction of the rearrangement of host actin was caused by an effector of the
Burkholderia secretion apparatus (Bsa) type III secretion system, termed BopE (85).
Capsular Polysaccharides
Capsule production has been shown to be an important virulence factor for many bacteria
that are pathogenic in humans. In B. pseudomallei, the capsular polysaccharide is encoded by
the wcb operon (100). Through electron microscopy, it has been established that there are three
distinct morphological states of B. pseudomallei: those possessing a macrocapsule (0.1-0.25μm
thick), those possessing a microcapsule (0.086μm thick) and those lacking a capsule (1). The
10

capsular polysaccharide, designated as type I O-PS, is a polymer of -3)-2-O-acetyl-6-deoxy-β-Dmanno-heptopyranose-(1- (74). It protects the bacterium from serum killing by reducing levels
of complement C3 deposition. Although C3 deposition is not completely eliminated, as has been
shown by the use of a mouse monoclonal antibody against human C3, the decrease in adherence
is enough to limit the effectiveness of opsonization and phagocytosis (74). It was also
demonstrated, by Reckseidler-Zenteno, et al, that in the presence of human serum, a B.
pseudomallei mutant strain lacking a capsule was phagocytosed more readily than the wild type
(74). The capsule has been shown to be important for the pathogenesis of B. pseudomallei in
that mutants unable to produce functional capsule polysaccharides are attenuated significantly
(100). Capsules also function as a form of protection against antibiotics. B. pseudomallei is able
to form microcolonies: this not only aids in protection against antibiotics, but also phenotypically
alters the bacteria themselves, making them less susceptible to some antibiotics. It has also been
shown that the capsule may play a role in intracellular survival of the bacterium (103).
Biofilm Formation
A biofilm is an aggregate of bacteria where cells have either adhered to a surface or
simply to each other by using an extracellular polymeric substance that they are able to produce
themselves. Many bacteria are able to form biofilms, and it is thought that the formation of a
biofilm is an important factor in many chronic infections. Cells within a biofilm are
physiologically and phenotypically distinct from planktonic cells. One characteristic of bacteria
in a biofilm is an increased resistance to antibiotics as compared to the planktonic bacteria; this
resistance can be increased by as much as 1,000 times (87). B. pseudomallei’s highly hydrated
glycocalyx capsule facilitates the formation of biofilms. In electron micrographs of B.
pseudomallei-infected lung tissue from guinea pigs and humans, biofilms have been
11

demonstrated (1). Although biofilm formation appears not to be essential for virulence of B.
pseudomallei, it almost certainly plays a role in survival in harsh environments (1).
Lipopolysaccharide
The lipopolysaccharide (LPS) of B. pseudomallei is also known as type II O-PS and has a
structure of -3)-β-D-glucopyranose-(1-3)-6-deoxy-α-L-talopyranose-(1- (74). There are three
distinct antigenic types of LPS described for B. pseudomallei: two smooth, serotypes A and B,
and a rare rough serotype. There is no cross reactivity seen between the three types, but they all
possess similar endotoxic levels and similar macrophage activation levels (1). Much like the
capsular polysaccharide, the LPS is important for virulence of B. pseudomallei. In mice and
diabetic rats, there is a reduction in lethality of infection when the animals are treated with
antibodies against the LPS (77). The LPS of B. pseudomallei has different characteristics than
those from other gram negative bacteria: B. pseudomallei’s LPS possesses weaker pyrogenic
activity in mice than enterobacterial LPS but has stronger mitogenic activity in the splenocytes of
mice (4). Arjcharoen, et al, also showed that the LPS of B. pseudomallei exhibits weaker and
slower activation kinetics for mouse macrophage cell lines; this could be due in part to the
unique structure of the LPS, as the chemical composition of the acid-stable inner core, which is
attached to a lipid A moiety, is atypical (4).
O-Antigen
The O-polysaccharide moiety of B. pseudomallei’s LPS has been shown to play an
important role in evasion of the innate immune system. It is involved in the invasion and
survival in macrophages and is able to modulate macrophage activation (4). Since activation of
iNOS may be an important early step in the destruction of this bacterium, the ability to inhibit
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macrophage activation may be important in its survival. Studies have shown that mutant strains
with alterations in the O-antigen structure are attenuated in animal models of melioidosis (77).
Flagella
Motility is an important virulence factor in many bacterial species as it aids their ability
to invade and replicate within both phagocytic and non-phagocytic cells. Flagella are also
important in the dissemination of bacteria from localized sites of infection. B. pseudomallei is
motile by means of flagella and thus contains the fliC gene, which encodes flagellin, the protein
from which flagella are constructed. Flagella may not be critical for virulence as no attenuation
was seen in experiments using diabetic rats and Syrian hamsters infected with a mutant strain of
B. pseudomallei with an altered fliC gene (22). Bacterial flagellin is recognized as a strong
stimulator of the immune system and it has been shown that anti-flagellin antibodies, used to
passively immunize diabetic rats, can reduce the median lethal dose of B. pseudomallei (18).
While flagella may not play an essential role in the virulence of B. pseudomallei in animal
models, it has been shown to be important for adherence to initiate bacterial entry into amoeba
(1, 23).
Pili
Both adherence to, and colonization of host cell surfaces are important first steps in the
establishment of an infection. Pili often mediate non-intimate adherence to host cells. Boddey,
et al, established that B. pseudomallei uses a type IV A pilin, encoded by the pilA gene, to adhere
to eukaryotic cells in vitro (specifically, human cervical carcinoma cell line ME180) (8). Type
IV pili typically aid bacteria in forming biofilms and microcolonies, which are both important for
virulence as discussed previously, however, it has been demonstrated that pilA is not required for
biofilm formation (8). In the B. pseudomallei genome, eight loci have been identified that
13

encode seven putative pilin subunits, which may explain this organism’s ability to infect such a
broad range of hosts (32).
Quorum-Sensing
Quorum sensing is a form of cell-to-cell communication that is density dependent and
modulates many diverse biological functions of gram-negative bacteria, such as
exopolysaccharide and extracellular enzyme production, biofilm formation, and expression of
extracellular virulence factors. At high densities, cells produce and respond to N-acylhomoserine
lactone (AHL) autoinducers. This process relies on two proteins: an AHL synthase, of the LuxI
family, which directs synthesis of AHL; and, belonging to the LuxR family, a transcriptional
regulator, which binds AHL and activates or represses targeted genes (96). Two quorum-sensing
systems have been characterized for B. pseudomallei: the PmlI-PmlR system and the BpsI-BpsR
system, both of which are required for full virulence of this organism. The PmlIR system
modulates the production of a protease, MprA, and at high autoinducer concentrations, PmlR
appears to repress expression of MprA (96). The BpsIR quorum-sensing system controls the
secretion of exoproducts in B. pseudomallei (83). This pathogen has at least two efflux pumps,
BpeAB-OprB and AmrAB-OprA. BpeAB-OprB is a multidrug efflux pump that is responsible
for conferring resistance to macrolides and aminoglycosides (15). It is thought that it is quorumregulated and in addition to antibiotic resistance, it also is necessary for production of quorumsensing-controlled virulence factors, such as a siderophore and biofilm components (15).
Because of the importance of BpeAB-OprB in the production of certain virulence factors, it is
recognized as an important virulence determinant.
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Type III Secretion System
Type III secretion systems (T3SS) are large assemblies of proteins spanning the inner
bacterial membrane, the periplasmic space, the peptidoglycan layer, the outer bacterial
membrane, the extracellular space and penetrating the host cell membrane. These systems are
used to transport effector proteins into host cells under specific conditions in an ATP-dependent
manner (31). The genome of B. pseudomallei contains three putative T3SS with the locus
designated Bsa for Burkholderia secretion apparatus (1). The T3SS involves an injectosome, a
hollow tube which acts as a needle, through which the effectors travel. This subunit is made up
of repeating units of BsaL (108). The translocon is the ring-like assembly that spans the host
cell’s membrane, through which translocator proteins travel into the host cell, causing inhibition
of certain functions which aid the bacterium in its survival (31). The Bsa effector proteins are
termed Bop (Burkholderia outer protein) and the translocators are termed Bip (Burkholderia
invasion protein) (99). The T3SS has been shown to be important in virulence of B.
pseudomallei in many of the animal models used. It has been shown that mutations in either
bopA and bopE cause attenuation of virulence in animals, while disruption of the bipD gene
reduces the organism’s ability to invade eukaryotic cells and reduces its virulence in mice (31).
BipD is believed to act as an extracellular chaperone which aids the translocator proteins in
entering the target cell, where they then form a pore (47). B. pseudomallei is unique among
facultative intracellular bacterial pathogens in that it is able to induce host cell fusion, which
leads to multinucleated giant cell (MNGC) formation in tissue culture models. By inactivating
the bipB gene, MNGC formation was reduced as was intracellular spread; this mutant was also
significantly diminished in its ability to cause infection in mice (86). Bsa T3SS mutants have
been shown to be attenuated as well; both in the mouse and Syrian hamster infection models.
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These mutants have a reduced ability to escape from endocytic vesicles and decreased
intracellular replication, and are not able to form actin tails or MNGC; all of these factors are
associated with B. pseudomallei virulence (41). Serum from melioidosis patients has been
shown to react with purified translocation proteins (BipB, BipC, and BipD), indicating that the
T3SS is functional in vivo (1).
Type VI Secretion System
Type VI secretion systems (T6SS) have been recently characterized as protein transport
mechanisms used by many gram-negative bacteria, and Burtnick, et al, has demonstrated that
they are key virulence determinants (14). Although not much is yet known about the structure
and function of these secretion systems, evidence suggests that they have features similar to
bacteriophage tail complexes (14). The genome of B. pseudomallei contains six putative T6SS
coding regions, which is more than any other bacterium known. It is likely that these T6SSs play
a role in virulence and it is likely that having such a large number of them (approximately 2.3%
of the genome) allows the organism to occupy a large range of niches (80). It has also been
demonstrated by Shalom, et al, that one of the T6SS is important for the uptake by, and invasion
of macrophages (79).
Siderophore
Iron is essential for bacterial growth. In order to establish and persist in a host, bacteria
must be able to acquire iron. In mammalian hosts, most of the iron is bound to proteins, such as
lactoferrin (in mucosal secretions) and transferrin (in plasma) or is located intracellularly and is
not accessible to the bacterium. To counter this, many bacteria secrete low-molecular-weight
iron chelators, called siderophores, which compete with host proteins for iron. Siderophores
have been implicated in the virulence of many different pathogenic bacteria. B. pseudomallei is
16

no exception and needs iron to survive within a host, and thus possesses a siderophore which is
able to remove iron from both lactoferrin and transferrin (105, 106). This siderophore was
termed malleobactin by Yang, et al (105). Since B. pseudomallei infections are initiated at the
mucosal surface, its ability to obtain iron from lactoferrin may be important in initiating an
infection (106).
Protease
A serine metalloprotease, MprA, has been described for B. pseudomallei, but it is not
required for infection in mice (1, 51). A 52 kDa calcium-dependent serine protease has also been
observed in this organism, and it has been shown to cause tissue necrosis (1). A 42 kDa and a 65
kDa protease have also been discovered, but their roles in pathogenesis are currently unknown
(1, 36).

Homology to species in the Burkholderia genus
It has been suggested that B. pseudomallei, B. mallei, and B. thailandensis represent three
states of ecological niche adaptation: opportunistic pathogen, obligate pathogen, and saprophyte,
respectively (56). It has also been proposed that Australian members of this species may be
ancestral to those from Southeast Asia: this is known as the Gondwana hypothesis (24).
Taxonomy
The Burkholderia genus comprises more than 30 species. These species are able to
inhabit many different and diverse ecological niches and have been isolated from soil, water,
plants, infected humans and animals, hospital and industrial settings, and insects. This genus
was defined to accommodate most of the former rRNA group II pseudomonads (29).
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Burkholderia thailandensis
B. thailandensis is a gram-negative saprophyte that is readily found in the environment in
Southeast Asia. It is closely related to both B. pseudomallei and B. mallei but shows reduced
virulence in comparison, with a much larger infectious dose of B. thailandensis needed to cause
disease in animal models (72). The 16S rRNA sequences of B. pseudomallei and B.
thailandensis differ by 15 nucleotides which are lacking in B. thailandensis (70, 75). The LPS of
B. thailandensis shares structural similarities to the LPS of B. mallei and B. pseudomallei, and it
has been demonstrated that antibodies against the LPS of B. pseudomallei can be detected using
the LPS of B. thailandensis in indirect immunofluorescent assays (72). Both B. pseudomallei
and B. thailandensis are motile by means of flagella and the fliC gene shows 99% amino acid
homology (23). Also highly conserved between the two species is the Bsa T3SS-encoding
region, although in arabinose-containing media, the T3SS of B. thailandensis is negatively
regulated (41). B. thailandensis is also able to induce cell fusion and the formation of MNGCs
after ingestion by phagocytes (63).
Key differences between B. pseudomallei and B. thailandensis
The gene cluster that encodes the capsular polysaccharide in B. pseudomallei is absent in
B. thailandensis, even though much of the wcb capsule operon genes are present in its genome;
thus it does not express a capsule (77). Even with the lack of a capsule, it is shown to be
resistant to serum killing, yet is unable to cause bacteremia in a Syrian hamster model (74). The
lack of a capsular polysaccharide contributes to its lower virulence. The B. thailandensis
genome contains an arabinose-assimilation operon that is lacking in B. pseudomallei (37). While
the genome of B. thailandensis encodes the fliC gene, it also possesses another flagellin gene,
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flagellin D, which is absent in B. pseudomallei (23). B. pseudomallei produces significantly
higher amounts of biofilm compared with B. thailandensis.
Differences between B. pseudomallei and B. mallei
B. mallei is an obligate mammalian pathogen and is the causative agent of glanders, a
disease affecting primarily equines but humans and other animals as well. Human cases are rare
and are usually laboratory acquired or associated with the handling of infected animals. It is
believed to be endemic in Southeast Asia, some parts of Africa, Central and South America, and
the Middle East (3). Using multi-locus sequence typing, it has been demonstrated that B. mallei
evolved from B. pseudomallei (76). The quorum-sensing systems of B. mallei are very similar to
those of B. pseudomallei with the exception of one luxIR pair (29). Both B. pseudomallei and B.
mallei are intrinsically resistant to many antimicrobials. However, while the former is resistant
to gentamicin, B. mallei is susceptible due to the deletion of the AmrAB-OprA efflux pumpencoding genes (78). Although there are some differences in antimicrobial susceptibilities,
treatment for both melioidosis and glanders is the same. B. mallei expresses a heterogeneous
mixture of acylated lipid A species, instead of the lipid A expressed by B. pseudomallei (13, 72).
B. mallei contains the gene cluster which encodes the capsular polysaccharide, but does not
contain the regions coding for the type III or type IV secretion systems. Because these two
secretion systems are conserved in B. thailandensis, it is thought that perhaps they play a role in
environmental survival (77).
Homology to other species
The exopolysacchrides of gram negative bacteria are divided into two groups, I and II, on
the basis of modes of expression and structural features. The exopolysaccharide of B.
pseudomallei is placed in group I, based on knowledge about its high molecular mass (>150
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kDa) and the temperature at which it is able to be expressed (below 20 C) (84). As has been
seen with Salmonella, Shigella, and Listeria, B. pseudomallei is able to induce caspase-1dependent cell death in monocytes and macrophages (12). Two of the putative T3SS of B.
pseudomallei show similarities to those of the plant-like pathogen Ralstonia solanacearum (41).
It is thought that these secretion systems allow the organism to interact with the plants in rice
paddies, where B. pseudomallei is typically found. The other T3SS (Bsa) shares significant
homology to the T3SS found on the Shigella flexneri virulence plasmid and Salmonella enteric
serovar Typhimurium pathogenicity island 1 (41, 108). Also, several Salmonella T3SS-delivered
effector homologues have been found in the T3SS gene cluster of B. pseudomallei; this includes
homologues to SopA and SopE, SipB and SipC, and IacP and IagB (99). One gene identified in
B. pseudomallei showed a weak sequence homology to a P. aeruginosa glycosyltransferase that
is important in capsule synthesis, while other genes involved in capsule synthesis show a strong
homology to those of Neisseria meningitidis, Haemophilus influenzae, and Escherichia coli (75).

Animal Models
Although melioidosis manifests itself in many different forms, animal models currently
focus on pathogenesis of acute disease. Syrian hamsters and diabetic rats are incredibly
susceptible to infection, and are used as models for acute disease (107). BALB/c mice are highly
susceptible to infection with B. pseudomallei, while C57BL/6 mice are 104 times more resistant
to disease (90, 93). Assays for determining virulence levels of different strains of this organism
are performed using BALB/c mice. It has also been shown that levels of mRNA for certain
cytokines, such as IFN-γ, are higher in BALB/c mice than in C57BL/6 (90, 95). While mice are
often used as models of infection, few studies have been attempted to study long-term latency.
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While a study in 1982 described experimental B. pseudomallei infection in goats, there are not
many reports of large animal models of infection with this organism (90).

Vaccination
Both B. pseudomallei and B. mallei are listed by the CDC as category B select agents
because of their high potential for weaponization and their high antibiotic resistance (39).
Despite this, there is currently no licensed vaccine available for either organism. Many
successful human vaccines are based on the use of capsular polysaccharide and capsular
polysaccharide conjugates. This has led to the belief that the capsular polysaccharide of B.
pseudomallei could be used to form part of a useful human vaccine (100). In addition, the
capsule is the dominant structure recognized by the immune system of patients that show
seropositivity (57, 100). Immunization with purified solutions of this polysaccharide were
shown to provide protection against intraperitoneal inoculation with B. pseudomallei in mouse
models, however, no protection was seen against airborne challenge (10, 100). The high genetic
similarity between B. pseudomallei and B. mallei strengthens the belief that a single vaccine may
be able to prevent or treat both melioidosis and glanders. Previous studies have shown that
subunit vaccines based on certain common polysaccharides were protective against both
organisms (76). However, due to the high degree of antigenic variation between strains of B.
pseudomallei alone, a vaccine that is based on a single antigenic determinant may not be
protective against all strains (5). It has also been shown that vaccines using inactivated bacteria
failed to induce the same level of immunity seen when live bacteria were used; thus the presence
of living bacteria may be important to generate sufficient protection (10). B. thailandensis has
been investigated as a potential vaccine candidate. Guinea pigs vaccinated with this organism
were shown to be protected against challenge with a lethal dose of B. pseudomallei (41).
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However, since B. thailandensis has been shown to be able to cause disease in humans, using
this organism as a live vaccine may not be feasible.

Diabetes
Type-1 diabetes mellitus is an autoimmune disease caused by the destruction of the
insulin-producing beta cells in the pancreas by autoreactive T cells. It manifests often during
childhood or early adulthood when at least 70% of the beta cell mass has been destroyed and
there is no longer sufficient insulin being produced (65). This disease is characterized by blood
glucose dysregulation, insufficient insulin production, hyperglycemia, and other long-term
complications (52). Type 1 diabetes mellitus has been studied extensively, yet the complete
immunological mechanisms responsible for the destruction of the pancreatic beta cells is not
completely clear; genetic predisposing factors and possible environmental triggers are likely
involved (38).
Many types of infections are seen more frequently in diabetic patients than in those
without diabetes (45).

The innate immunity of patients with diabetes mellitus has been shown

to be altered, especially in terms of PMNL function, when compared to the innate immunity of
non-diabetic patients. Diabetic PMNLs show reduced migration in response to IL-8 compared to
those from healthy subjects and have been shown to have reduced phagocytic capacity (16).
Macrophages have been shown to be impaired as well, possibly causing the increased
susceptibility to many gram-negative infections seen in those with diabetes (71). Poor glycemic
control may have an effect on cell function, as immune function has been seen to improve as
glycemic control improves (45, 59). Phagocytosis is greatly impaired in cases of poor glycemic
control, as well as the ability of granulocytes to kill engulfed bacteria (6, 66). HbA1c levels are
used to determine the average plasma glucose concentration. While the American Diabetes
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Association recommends having an HbA1c level below 7.0, those with diabetes often have levels
above this.

The Current Study
Previous research by Laura Dickey (27) showed that cytokine profiles of monocytes
infected with B. pseudomallei are highly dependent on both gender and diabetic state.
Monocytes from diabetic males were shown to produce significantly less proinflammatory
cytokines, especially IL-1β and IL-8, than those from healthy, age-matched controls, when cells
were infected with not only B. pseudomallei, but B. thailandensis and E. coli as well. Monocytes
from diabetic females were shown to actually produce significantly more IL-1β when infected
with B. pseudomallei than those from healthy, age-matched controls. The study by Dickey
involved a small sample population and the cells used were monocytes, precursors to
macrophages. It was hypthothesized that if macrophages were used for infections instead of
monocytes, the differences that were shown to be dependent on diabetic state and gender would
be more robust. It was also decided that doubling the sample population would give more
conclusive results. The purpose of this study was to determine the effect of gender and diabetic
state on levels of proinflammatory cytokines produced by M1 macrophages infected with B.
pseudomallei, B. thailandensis, and E. coli, compared with uninfected controls. Preliminary
studies were performed on macrophages from a diabetic male to prove feasibility. Results from
these studies were similar to those reported by Dickey. Therefore, the full study was
subsequently undertaken.
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Materials and Methods
Blood Donors
Persons with type I diabetes mellitus and healthy controls, matched for age and gender, were
recruited using fliers and personal communication. Protocols involving human blood donors
followed federal regulations and were approved by the Brigham Young University Institutional
Review Board (IRB).

Bacteria
Bacteria strains used were Escherichia coli ATCC 11229, Burkholderia thailandensis ATCC
700388, and Burkholderia pseudomallei NCTC 13178. B. pseudomallei 13178 was originally
isolated from a patient admitted to the Townsville General Hospital (Townsville, Queensland,
Australia) and its virulence has been previously documented (7).

Relationship of Turbidity to Cell Concentration
Bacteria were grown overnight in 5 ml of Brain Heart Infusion (BHI) broth in 15-ml conical
tubes at 37 C in a shaking incubator at 250 rpm. Cultures were centrifuged at 3,838 xg, washed,
and resuspended in 5 ml of supplemented RPMI media. Serial dilutions were made for each
species (1:2, 1:3, 1:4, 1:6, 1:8, 1:10, 1:16, and 1:64). Spectrophotometer readings were recorded
for each dilution and 1-ml samples of dilutions 1x10-5, 1x10-6, and 1x10-7 (for E. coli), 1x10-6,
1x10-7, 1x10-8 (for B. thailandensis), and 1x10-7, 1x10-8, and 1x10-9 (for B. pseudomallei) were
plated in triplicate on Columbia agar plates using membrane filtration. Plates were incubated at
37 C. Colony forming units (CFU) were counted 24-48 hours later. Regression lines of percent

24

transmittance versus log cell concentration were created using MiniTab 16 Statistical Software
(MiniTab Inc.) and used to determine bacterial concentrations for all subsequent infections.

Monocyte Separation from Whole Blood
Fifty ml whole blood was collected from donors in K2 EDTA (K2E) vacutainers (Becton
Dickinson). Twenty-five ml of whole blood was diluted in 10 ml of Hanks Balanced Salt
Solution (HBSS; HyClone). Approximately 35 ml of blood-HBSS was carefully layered over 15
ml of Lymphocyte Separation Medium (LSM; Cellgro) and centrifuged at 600 xg for 20 minutes
at 20 C. Approximately 15 ml of peripheral blood mononuclear cells (PMBCs) were removed
and mixed with 4 ml of OptiPrep reagent (Sigma Aldrich). This was overlaid with 7.5 ml and 20
ml of Optiprep solutions with densities of 1.084 g/ml and 1.068 g/ml, respectively. Cells were
centrifuged at 800 xg for 25 minutes at 20 C. The top 20 ml were then removed, centrifuged
and washed twice. Cells were counted and resuspended in the appropriate amount of RPMI
medium (HyClone) supplemented with 20% heat-inactivated FBS (Atlanta Biologicals), 1%
sodium pyruvate (HyClone), 0.2% HEPES (OmniPur), 0.02% gentamicin (Atlanta Biologicals),
and 10% human serum (pooled from four to five healthy donors) to give 1 x 106 cells per well of
a Costar 12-well cell culture plate (Corning).

GM-CSF Preparation
Granulocyte-macrophage-colony stimulating factor (GM-CSF; Millipore) was dissolved in
sterile water. A stock solution at a concentration of 0.1-1.0 mg/ml was made and aliquots were
stored at -20 C until use.
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Macrophage Culturing
GM-CSF, at a concentration of 0.5 ng/ml, was added to each well of separated monocytes. The
cell culture dishes were incubated at 37 C with 5% CO2 for 24 hours.

Fluorescence Microscopy
Once monocytes were separated from human whole blood and allowed to differentiate into
macrophages for 24 hours, fluorescence microscopy was performed to assure that adherent cells
were indeed macrophages. Cells were washed twice with 1 ml of Dulbecco’s Phosphate
Buffered Saline (DPBS; Atlanta Biologicals). Macrophages were stained with anti-CD14
antibody by flooding each well with 500μl of DPBS to which 10μl of anti-CD14 antibody
conjugated with R-Phycoerythrin (PE; Invitrogen) was added. Cells were incubated at room
temperature for 15 minutes and then washed twice with 500μl of DPBS. A final volume of
500μl of DPBS was added and cells were visualized under fluorescence microscopy.

Bacterial Cultures
Overnight cultures of each of the three bacteria were grown in 5 ml of BHI broth at 37 C in a
shaking incubator at 250 rpm. Suspensions of approximately 107 cfu/ml were made in
supplemented RPMI media (10% FBS, 1% HEPES, and 1% sodium pyruvate) using the turbidity
regression lines.

Infection
Infections were performed using the three aforementioned bacterial strains and a mock infection
(in which no bacteria were added) was included as a control. Cells were washed three times with
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DPBS prior to addition of 1 ml of bacterial suspension (at 107 cfu/ml). Infections were
performed at a multiplicity of infection (MOI) of 10:1 (bacteria to macrophages) in RPMI media.
After 90 minutes, 200 μg/ml of kanamycin was added to each well. Total RNA was extracted
from each well at six hours post-infection.

RNA Extraction and cDNA Synthesis
Total RNA was extracted from the macrophage cultures using SurePrep TrueTotal RNA
Purification Kit (Fisher Scientific) according to the manufacturer’s instructions. The RNA was
quantified using a NanoDrop (ND-1000, V3.3.0) and cDNAs were synthesized using a
QuantiTect Reverse Transcriptase (RT) Mix (Quiagen). The cDNA was used as the template in
qPCR reactions.

Real-Time PCR and Determination of Relative Expression Levels
All PCR reactions were performed using an ABI Prism 7900HT (Applied Biosystems).
Reagents used in reactions were from the QuantiTect Probe RT-PCR kit and included RNaseFree water and RT-PCR Master Mix. Expression of both IL-1β and IL-8 mRNA was determined
using oligonucleotide primers from Integrated DNA Technologies (TABLE 1). The TATA
binding protein (TBP) mRNA was used as an internal control (TABLE 1). The results were
presented as Ct values. Ct is defined as the cycle at which the amplified product crosses the
threshold. ΔCt was the difference in the Ct values of the gene of interest (IL-1β or IL-8) and the
TBP. The ΔCt for each experimental sample (infected samples) was subtracted from the ΔCt of
the control sample (the uninfected, or mock, samples). This difference is designated ΔΔCt. The
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relative level of the difference of the gene of interest mRNA expression from that of a mock
infection was reported as log(2-ΔΔCt), or the log of the fold expression (54).

ELISA Assays
Cells were infected with bacterial cultures, as described above, and at 6 hours post infection,
supernatants were collected and filtered using Acrodisc Syringe Filters (Pall Corporation) to
ensure removal of cells. Supernatants were stored at -80 C until use. Supernatants from select
samples were measured for IL-1β and IL-8 using a QuantiGlo Chemiluminescent Immunoassay
(R&D Systems) according to the manufacturer’s instructions.

Statistical Analysis
The IL-1β and IL-8 PCR data were transformed to the logarithmic (base 10) scale before
analysis. Data were analyzed using mixed linear models with species of bacteria, sex of subject,
diabetic status of subject, and age of subject, as well as interactions of these factors as predictors.
Subjects were used as a random effect in the models. Residual plots were used to assess
goodness of fit of the models. Models with interactions were compared to main effect models
using likelihood ratio tests. Means for significant factors were compared using pairwise t-tests.
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Results
Monocytes differentiate to macrophages are produced after a 24 hour incubation with GM-CSF
Many protocols and culture conditions were tested to determine those best suited for
producing type-1 macrophages from monocytes separated from human whole blood. Monocytes
from healthy donors (both male and female) were separated from whole blood using density
gradients. These cells were incubated with GM-CSF for 24 hours. Examination of the cultures
using phase microscopy revealed adherent cells with morphologies characteristic of
macrophages. In situ staining with PE-labeled anti-CD14 antibody confirmed the cells to be
macrophages (Figure 2 A and B). These cells were infected for a period of six hours using one
of four infection schemes. The six-hour time-point was chosen based on similar macrophage
infection studies and preliminary testing (70).
Macrophages produce IL-1β and IL-8 when infected with B. pseudomallei, B. thailandensis, and
E. coli
A preliminary infection (Figure 3) was performed to insure that macrophages isolated
from a healthy subject and infected with bacteria were able to produce both IL-1β and IL-8 at
levels higher than those produced by uninfected cells. Monocytes were isolated from human
whole blood, differentiated to macrophages for 24 hours in the presence of GM-CSF, and then
infected with B. pseudomallei, B. thailandensis, and E. coli in triplicate. After six hours, mRNA
was collected and qPCR was performed. Infected macrophages produced greater than a 2.5 log
fold increase of IL-1β and almost a two log fold increase of IL-8, with B. pseudomallei-infected
cells producing slightly less proinflammatory cytokines than macrophages infected with either B.
thailandensis or E.coli.
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Use of kanamycin does not affect cytokine production
Kanamycin was added 90 minutes after infection with each organism to inhibit
extracellular growth of the bacteria. To be certain that the use of kanamycin was not affecting
the production of mRNA for either cytokine, a six hour infection with E. coli was performed
with and without kanamycin. As seen in Figure 4, the use of kanamycin did not appear to
significantly alter the production of either IL-1β or IL-8.
Preliminary testing with a single diabetic male and an age-matched, healthy control showed
lower proinflammatory cytokine production by the diabetic
As seen in Figure 5, a preliminary infection using macrophages isolated from both a
diabetic male and an age- and gender-matched control showed a significant decrease in the
production of mRNA for both IL-1β and IL-8. Macrophages from the diabetic patient produced
significantly lower proinflammatory cytokines than those from the healthy control in response to
all three infectious agents.
mRNA transcript levels of IL-1β and IL-8 correlate generally with protein production
The first full set of infections (one male diabetic, one female diabetic, and their age- and
gender-matched controls, Figure 6 A and B) produced results that differed from those of the
preliminary infection reported above. Infected macrophages from the diabetic male showed little
difference in comparison to those from the healthy control subject, with regards to cytokine
production. However, cells from the diabetic female produced lower levels of IL-1β and IL-8
compared to those from the healthy control. To confirm that this was true of both the mRNA
and the protein itself, an ELISA for IL-1β was performed on culture supernatants. As seen in
Figure 6 C, the production of both IL-1β transcript and protein correlated significantly with each
other (p<0.012). All samples of both mRNA and protein collected from cells which had been
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infected with bacterial agents were normalized against the corresponding concentrations of
mRNA and protein in mock infected cells.
Diabetes and gender showed no statistically significant difference with respect to
proinflammatory cytokine profiles of macrophages infected with B. pseudomallei
A total of 40 volunteers were included in this complete study: ten diabetic males and ten
healthy male age-matched controls, and ten diabetic females and ten healthy female age-matched
controls. When the means of the complete data were analyzed, diabetes and gender were not
significant factors in the production of IL-1β and IL-8 in response to infection with B.
pseudomallei, B. thailandensis, or E. coli (Figure 7).
Age of subject may be a significant factor in the mean fold increase in IL-8 production in
response to infection
Subject ages ranged from 18 to 57 (Table 2). Age was a significant factor in the
production of IL-8 in response to infection, with the mean production of transcript increasing by
a factor of 1.066 per year of age (p<0.01). However, this affect was based upon the participation
of only one pair of older females, both 57 years of age. Data from a larger number of older
subjects are needed to confirm this trend.
Cytokine production differed depending on infectious organism
As expected, cytokine responses varied depending on the organism used to infect
monocyte-derived macrophages. In the case of IL-1β transcript production, a significantly lower
response was seen when macrophages were infected with B. thailandensis as compared to either
B. pseudomallei or E. coli (Figure 8 A). Production of IL-8 mRNA was upregulated most when
the infectious agent was E. coli, while little differences were seen between B. pseudomallei and
B. thailandensis (Figure 8 B).
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HbA1c levels of volunteers used in this study were all similar
As seen in Table 3, the HbA1c levels of all donors who participated in the study were
similar, with a mean HbA1c of 7.5, and a range from 6.0-13.0. Three participants did not know
their HbA1c levels.
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Discussion
Previous research (Laura Dickey) from our lab showed that there were significant
differences in the production of both IL-1β and IL-8 by monocytes infected with B. pseudomallei
based upon gender and diabetic state (27). It was demonstrated that diabetic males produced
significantly less IL-1β and IL-8, as well as less TNF-α and IL-6, when compared to healthy,
age-matched males, while monocytes derived from diabetic females showed an increase in the
production of IL-1β when compared to those from healthy, age-matched females. Since blood
monocytes may not be the first cell most commonly encountered by B. pseudomallei early in the
infectious process, we wanted to determine whether macrophages would respond similarly.
In this study, similar work to that of Laura Dickey was performed except macrophages
and a larger sample size (twice the number used before) were used, and levels of IL-1β and IL-8
were followed using qPCR. Macrophages are known to have greater immune response
capabilities when challenged with microbial agents. Using these parameters, we hypothesized
that significant effects due to gender and diabetic state would be amplified, possibly clarifying
the dramatic susceptibilities of male diabetic patients to disease caused by B. pseudomallei.
Type I diabetes mellitus is a disease that affects multiple body systems. It is believed to
be an autoimmune disease that is caused by the destruction of the insulin-producing beta cells in
the pancreas. This leads to insufficient insulin production and blood glucose dysregulation,
which affects immune function (52). Patients with diabetes mellitus appear to be more
susceptible to certain bacterial infections than those who are healthy (45). The innate immunity
of patients with diabetes mellitus has been shown to be altered, especially key neutrophil
functions. For example, neutrophils from diabetics show not only reduced migration, but
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reduced phagocytic capacity as well, compared to those from healthy subjects (16). Critical
functions of macrophages from diabetics have been shown to be negatively altered as well (71).
Though past research demonstrated an impairment of immune function in monocytes from
diabetic males, the results of the current study show that macrophages differentiated in the
presence of GM-CSF and normal human serum for 24 hours do not demonstrate these same
impairments. These results suggest that macrophages that have differentiated outside of the
diabetic environment seemed to have regained functions lost by diabetic monocytes, leading to
monocyte-derived macrophages that now behave similar to those that came from healthy donors.
It has been shown that glycemic dysregulation can influence immune cell function,
making it probable that once removed from the diabetic environment, macrophages are able to
regain normal immune functions. Macrophages and neutrophils from patients with poorly
managed diabetes mellitus have impaired immune functions (71). This was demonstrated by
both Bagdade, et al, and Nolan, et al, who showed increases in both phagocytic and killing
abilities in cells from diabetics, once the patient’s serum glucose levels were brought to normal
(6, 66). Nolan, et al, also showed that the intracellular killing of Staphylococcus aureus by
granulocytes from diabetics was markedly decreased in an inverse proportion to serum glucose
levels: the higher the glucose levels of the diabetic patient, and thus the less controlled the
diabetic state, the less able the cells were to eliminate the bacteria (66). In addition, a study by
McMahon, et al, showed that leukocytes from diabetic patients exhibiting poor glycemic control
had impairments not only in phagocytosis and intracellular killing, but chemotaxis and
adherence as well (59). However, once serum glucose levels were reduced through treatment,
phagocytic cells recovered their normal abilities to phagocytose and eliminate bacteria (6, 45, 59,
66).
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In the current study, the average HbA1c level of all 20 diabetic donors was 7.5 (Table 3).
While this is slightly higher than the level recommended by the American Diabetes Association,
who recommends an HbA1c level below 7.0, all donors closely monitored their serum glucose
levels and took insulin daily.
Diabetics living within many of the regions in which B. pseudomallei is endemic most
likely have glucose levels less well managed, as many do not have access to adequate health
care. Without proper treatment and education, glycemic control would be less well managed and
elevated serum glucose levels would likely reduce the ability of those infected with B.
pseudomallei to fight infection. This may at least partly explain why diabetes mellitus is a risk
factor for melioidosis. Diabetes is also well documented as a risk factor for many other gram
negative infections (9, 45, 59, 71).
In Australia, indigenous status is a risk factor for melioidosis. In the northern part of the
country, aboriginal patients account for approximately half of all melioidosis cases (20). This
risk factor may be due to the high incidence of diabetes in the Aboriginal population. In a study
done by McDermott, et al, it was discovered that the incidence of diabetes in two groups of
indigenous people in Australia was almost four times higher than that reported in the general
population (58). Depending on location, proper diabetes care may not always be available,
which implies that within the Aboriginal population, diabetes may run unchecked, leading to
poor blood glucose control (81). The aboriginals also tend to live traditionally which puts them
in close contact with the environment and the affects of the changing season, particularly heavy
rain (20).
Taking all of this into account, the normal responses of the macrophages used in this
study may be due to not only the donor’s excellent glycemic control, but by the fact that the cells

35

were cultured for 24 to 30 hours outside of the diabetic environment. These factors all could
have influenced the perceived ability of macrophages from diabetic donors to regain more
normal immune response capabilities.
Hormones and certain types of medications, such as steroids, have been shown to alter
the immune response. Production of cytokines, such as IL-1, IL-6, TNF-α, and TGF-β, by
monocytes and macrophages, can be affected negatively by estrogen (48, 62). Glucocorticoids
(GCs), which are commonly used to treat many illnesses such as asthma and allergies, as well as
other common medications, can also interfere with immune responses. GCs repress proinflammatory mediators and induce the synthesis of anti-inflammatory molecules (91). GCs are
known to suppress cytokine and chemokine production and cell adhesion molecules, and as
Tuckermann, et al, demonstrated, GCs can suppress macrophage functions (91, 92). GCs
interfere with macrophage function at many levels: they can hinder differentiation, proliferation,
and production of certain cytokines, including IL-1 and IL-8 (91). Although a short survey was
given to each of the diabetic donors to better understand their diabetic condition, no questions
regarding hormones or current medications were asked of either diabetic or non-diabetic donors.
Because estrogen is a common hormone used in birth control, and GCs, as well as other
medications, are prescribed to treat common maladies, any of these unknown factors could have
affected the results of this study.
It is known that age is also a predisposing risk factor for melioidosis, with individuals
over the age of 45 being more susceptible to infection with B. pseudomallei (19, 25, 73). It is
also well known that age is associated with a decline in immune function (28, 35, 68). In a study
done by Chen, et al, it was demonstrated that adults over the age of 60 are especially at risk for
infection with B. pseudomallei (17). In the previous research done by Laura Dickey, the sample
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population examined consisted of individuals that were over the age of 40. This study involved
donors that were between the ages of 19 to 27 years old, with only one pair of females over the
age of 40 (Table 2). The lower average age for those in this study may have also factored into
the results seen here.
The current study did show significant differences in cytokine production depending on
the infectious organism (Figure 8). Production of IL-1β mRNA was significantly lower
(p<0.001) in macrophages infected with B. thailandensis, while production of IL-8 mRNA was
significantly higher (p<0.0001) in those infected with E. coli. Infection with B. thailandensis
produced the lowest increase of both cytokines. B. thailandensis is rarely pathogenic to humans
and a significantly higher dose is needed for infection in animal models (41). It creates a strong
innate immune response and because of this response, B. thailandensis is able to be quickly
cleared from the host.
Results from this study were consistent with those from studies with E. coli, in that this
organism is a strong stimulator of the innate response due to its Lipid A component. Lipid A
plays an important role in stimulating the immune system, and E. coli has one of the most
biologically active forms of this molecule (67). The LPS of B. pseudomallei stimulates both
human and murine macrophages to produce less IL-6, IL-10, and TNF-α than does the LPS of
either B. thailandensis or E. coli, as demonstrated by Novem, et al (67). It was shown that the
LPS of B. pseudomallei causes a response from the host immune system that is different from
those generated by other gram negative bacteria: the LPS of B. pseudomallei has weaker
pyrogenic activity in mice (4). Arjcharoen, et al, also showed that the LPS of B. pseudomallei
exhibits weaker and slower activation kinetics for mouse macrophage cell lines (4). While this
study showed that IL-8 mRNA production was decreased in both Burkholderia species as
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compared to E. coli, the stimulation of production of IL-1β by B. pseudomallei was actually
higher than that of B. thailandensis (Figure 8). The macrophage culturing conditions used in this
study may have altered the cells responses to infection and may explain why the results from this
part of the study differ from what has been described previously.
Nearly all people in endemic regions are seropositive for B. pseudomallei, yet not all
have active disease. This reinforces the belief that host susceptibility may have a role in
melioidosis. While diabetes is a risk factor for melioidosis, male diabetics are known to be
particularly susceptible to infection with B. pseudomallei (25). Previous research has
demonstrated that monocytes from male diabetics produce a blunted proinflammatory cytokine
response when infected by B. pseudomallei (27). In the current study, monocytes were isolated
from diabetic and age-matched healthy controls using density gradients and cultured in media
containing normal human sera and GM-CSF. The addition of GM-CSF to the media has been
shown to produce M1 macrophages, which are known to produce proinflammatory cytokines
(98). After 24 hours, in situ staining of adherent cells with PE-labeled antibody against human
CD14 demonstrated the presence of macrophages. After a 6 hour infection with either B.
pseudomallei, B. thailandensis, or E. coli, total RNA was extracted from cells, quantified,
converted into cDNA, and qPCR was performed for the presence of IL-1β and IL-8 transcript.
All levels of mRNA were standardized to the levels of mock infected (uninfected) cells that were
run as a control for each experiment. When the means of the major factors were analyzed, it was
determined that under the conditions and parameters established for this study, diabetic state and
gender did not have an effect on the IL-1β and IL-8 responses of infected monocyte-derived
macrophages.
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The results of this study in combination with the research performed by Laura Dickey
indicate the importance of maintaining the diabetic condition throughout the infection process.
Once removed from the diabetic environment, macrophages seem to regain immune functions
similar to the functions of cells isolated from healthy donors. Thus, it is imperative that the
conditions under which differentiation and infection take place are as close as possible to the
original diabetic environment. This outcome will be valuable to future research investigating
effects of the diabetic state on immune cell functions and may have important implications
towards the treatment of diabetes.
Further testing will need to be performed to determine the effects of the diabetic
environment on the ability of macrophages to respond to infection. Studies using older diabetic
donors that have poor glycemic control and healthy age- and gender-matched controls will need
to be performed. By using serum from these donors in the differentiating environments in a
reciprocal crossover study, in which each type of macrophage will be incubated in each type of
serum, perhaps the true effects of the diabetic state can be determined. These studies are
currently underway.
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Table 1. Sequences of primers and probes used for q-PCR detection of log fold increases in
proinflammatory cytokines.

GENE

FORWARD PRIMER

REVERSE PRIMER

PROBE

IL-1β

5'-TGGAGCAACAAGTGGTGT-3'

5'-TTGGGATCTACACTCTCCAGC-3'

5'-CCTTGAGGCCCAAGGCCACA-3'--FAM

IL-8

5'-GCCAACACAGAAATTATTGTAAAGCTT-3'

5'-AATTCTCAGCCCTCTTCAAAAACTT-3'

5'-AGAGCTCTGTCTGGACCCCAAGGAAAAC-5'--TET

TBP

5'-CACGGCACTGATTTTCAGTTCT-3'

5'-TTCTTGCTGCCAGTCTGGACT-3'

5'-TGTGCACAGGAGCCAAGAGTGAAGA-3'--HEX
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Table 2. Ages of blood donors used in this study.
Male
Diabetic
Non-Diabetic

Female
Diabetic
Non-Diabetic

24

24

23

24

24

24

19

20

20

22

19

21

20

18

21

21

21

22

27

26

24

24

24

24

21

23

22

20

21

22

57

57

29

27

22

20

19

18

25

27
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Table 3. HbA1c levels of diabetic donors.
Subject

A1c level

M prelim
F1
M1
F2
M2
F3
M3
F4
M4
F5
M5
F6
M6
F7
M7
F8
M8
F9
M9
F10
M10

7.8
6
7.1
8.6-9
7.2
unknown
unknown
6.9
7.0-8.0
7.6
6.1
6.0-8.0
13
8.4
unknown
7.9
6.2
7.4
6.7
7.2
7.5
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Figure 1. The variable colony morphology of a pure culture of Burkholderia pseudomallei.
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Figure 2. Macrophages isolated from human whole blood. Using OptiPrep density gradients,
monocytes were separated from human whole blood and then allowed to grow and differentiate
into macrophages for 24 hours in supplemented RPMI with GM-CSF. Macrophages were
stained with PE-labeled anti-CD14 antibody and viewed under fluorescence microscopy at 10x
(A) and 20x (B).
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3

Log Fold Expression

2.5
2

B. pseudomallei

1.5

B. thailandensis
E. coli

1

0.5
0

IL-1β

IL-8

Figure 3. Log fold increase in expression of IL-1β and IL-8 in human macrophages infected
with B. pseudomallei, B. thailandensis, and E. coli. Cells were infected at an MOI of 10 and
mRNA was extracted at 6 hours post-infection. Total mRNA was assayed using qPCR.
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0.9
0.8

Log Fold Expression

0.7
0.6
0.5

E. coli

0.4

E. coli with kanamycin

0.3
0.2
0.1
0

IL-1β

IL-8

Figure 4. Effect of kanamycin on IL-1β and IL-8 mRNA production. Kanamycin was added 90
minutes p.i. Macrophages from a healthy male were infected with E. coli. mRNA was collected
6 hr p.i. and qPCR was performed. The use of this antibiotic did not significantly affect IL-1β or
IL-8 mRNA production.
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A.
IL-1β
3

Log Fold Expression

2.5
2
1.5

Diabetic

1

Healthy

0.5
0

B. pseudomallei B. thailandensis

E. coli

B.
IL-8

Log Fold Expression

2.5

2
1.5

Diabetic
1

Healthy

0.5
0

B. pseudomallei B. thailandensis

E. coli

Figure 5. IL-1β (A) and IL-8 (B) mRNA production by macrophages from a diabetic male and
an age-matched healthy control in response to infection with B. pseudomallei, B. thailandensis,
and E. coli. Monocytes collected from a male diabetic and an age-matched control were allowed
to differentiate to macrophages and were then infected at an MOI of 10. mRNA was collected 6
hr p.i. and qPCR was performed.
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A.

B.
Female IL-1β

2.5
2

1.5
1

Diabetic

0.5

Healthy

0

Log Fold Expression

Log Fold Expression

Male IL-1β
3
2.5
2
1.5
1
0.5
0

Diabetic
Healthy

C.
IL-1β Protein and mRNA Expression

Log Fold Expression

3
2.5
2
1.5
1
ELISA

0.5

PCR

0

Diabetic Female

Healthy Female

Diabetic Male

Healthy Male

Figure 6. Expression of IL-1β by infected macrophages from both male (A) and female (B)
diabetics and healthy age- and gender-matched controls. Monocytes were isolated from whole
blood, differentiated into macrophages and infected at an MOI of 10. mRNA and supernatants
were collected 6 hr p.i. (C). Supernatants were assayed for IL-1β levels using ELISA and IL-1β
mRNA was assayed using qPCR. IL-1β mRNA production and protein production correlated
significantly (p<0.01).
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Male IL-8
Log Fold Expression

Log Fold Expression

Male IL-1β

Diabetic
Healthy

C.

1.40
1.20
1.00
0.80
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0.40
0.20
0.00

Diabetic
Healthy

D.

1.40
1.20
1.00
0.80
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0.40
0.20
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Female IL-8

Diabetic
Healthy

Log Fold Expression

Log Fold Expression

Female IL-1β
1.40
1.20
1.00
0.80
0.60
0.40
0.20
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Healthy

Figure 7. Mean log fold increases in IL-1β and IL-8 mRNA by macrophages from both male and
female, diabetic and age-matched healthy controls, infected with B. pseudomallei, B.
thailandensis, and E. coli. Monocytes were isolated from whole blood and differentiated into
macrophages. Macrophages were then infected at an MOI of 10. mRNA was extracted at 6 hr
p.i. and qPCR was performed. Each point represents a mean of 10 experiments. Standard errors
are shown.
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A.
IL-1β
1.2

Log Fold Expression

1
0.8

*

0.6
0.4

0.2
0

E. coli

B. pseudomallei

B. thailandensis

B.
IL-8
1.2

Log Fold Expression

1

**

0.8
0.6
0.4
0.2
0

E. coli

B. pseudomallei

B. thailandensis

Figure 8. Mean log fold increase in IL-1β (A) and IL-8 (B) production by macrophages when
infected with B. pseudomallei, B. thailandensis, and E. coli, averaged across gender and diabetic
state. mRNA was extracted at 6 hr p.i. and qPCR was performed. Macrophages responded
differently to infection with each organism. Each value represents a mean of 40 experiments.
Standard errors are shown.
*indicates significant difference in cytokine production (p<0.001)
**indicates significant difference in cytokine production (p<0.0001)
Bar indicates no significant difference

50

References
1.

2.

3.

4.

5.

6.
7.

8.

9.
10.

11.

12.

13.
14.

15.

Adler, N. R. L., B. Govan, M. Cullinane, M. Harper, B. Adler, and J. D. Boyce. 2009. The
molecular and cellular basis of pathogenesis in melioidosis: how does Burkholderia
pseudomallei cause disease? Fems Microbiology Reviews 33:1079-1099.
Ahmed, K., H. D. R. Enciso, H. Masaki, M. S. Tao, A. Omori, P. Tharavichikul, and T. Nagatake.
1999. Attachment of Burkholderia pseudomallei to pharyngeal epithelial cells: A highly
pathogenic bacteria with low attachment ability. American Journal of Tropical Medicine and
Hygiene 60:90-93.
Antonov, V. A., Tkachenko, G.A., Altukhova, V.V., Savchenko, S.S., Zinchenko, O.V.,
Viktorov, D.V., Zamaraev, V.S., Ilyukhin, V.I., Alekseev, V.V. 2008. Molecular identification
and typing of Burkholderia pseudomallei and Burkholderia mallei: when is enough enough? .
Trans R Soc Trop Med Hyg. 102:134-139.
Arjcharoen, S., C. Wikraiphat, M. Pudla, K. Limposuwan, D. E. Woods, S. Sirisinha, and P.
Utaisincharoen. 2007. Fate of a Burkholderia pseudomallei mouse macrophage cell line
lipopolysaccharide mutant in the RAW 264.7: Possible role for the o-antigenic polysaccharide
moiety of lipopolysaccharide in internalization and intracellular survival. Infection and Immunity
75:4298-4304.
Atkins, T., R. G. Prior, K. Mack, P. Russell, M. Nelson, P. C. F. Oyston, G. Dougan, and R. W.
Titball. 2002. A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino
acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis.
Infection and Immunity 70:5290-5294.
Bagdade, J. D., K. L. Nielson, and R. J. Bulger. 1972. Reversible abnormalities in phagocytic
function in poorly controlled diabetic patients. Am J Med Sci 263:451-6.
Barnes, J. L., G. C. Ulett, N. Ketheesan, T. Clair, P. M. Summers, and R. G. Hirst. 2001. Induction
of multiple chemokine and colony-stimulating factor genes in experimental Burkholderia
pseudomallei infection. Immunology and Cell Biology 79:490-501.
Boddey, J. A., C. P. Flegg, C. J. Day, I. R. Beacham, and I. R. Peak. 2006. Temperature-regulated
microcolony formation by Burkholderia pseudomallei requires pilA and enhances association
with cultured human cells. Infection and Immunity 74:5374-5381.
Breen, J. D., and A. W. Karchmer. 1995. Staphylococcus aureus infections in diabetic patients.
Infect Dis Clin North Am 9:11-24.
Breitbach K, K. J., Steinmetz I. 2008. Induction of protective immunity against Burkholderia
pseudomallei using attenuated mutants with defects in the intracellular life cycle. Trans R Soc
Trop Med Hyg. 102:89-94.
Breitbach, K., K. Rottner, S. Klocke, M. Rohde, A. Jenzora, J. Wehland, and I. Steinmetz. 2003.
Actin-based motility of Burkholderia pseudomallei involves the Arp 2/3 complex, but not NWASP and Ena/VASP proteins. Cellular Microbiology 5:385-393.
Breitbach, K., G. W. Sun, J. Kohler, K. Eske, P. Wongprompitak, G. Tan, Y. C. Liu, Y. H. Gan, and
I. Steinmetz. 2009. Caspase-1 Mediates Resistance in Murine Melioidosis. Infection and
Immunity 77:1589-1595.
Burtnick, M. N., P. J. Brett, and D. E. Woods. 2002. Molecular and physical characterization of
Burkholderia mallei O antigens. Journal of Bacteriology 184:849-852.
Burtnick, M. N., D. DeShazer, V. Nair, F. C. Gherardini, and P. J. Brett. Burkholderia mallei
Cluster 1 Type VI Secretion Mutants Exhibit Growth and Actin Polymerization Defects in RAW
264.7 Murine Macrophages. Infection and Immunity 78:88-99.
Chan, Y. Y., and K. L. Chua. 2005. The Burkholderia pseudomallei BpeAB-OprB efflux pump:
Expression and impact on quorum sensing and virulence. Journal of Bacteriology 187:4707-4719.
51

16.

17.

18.

19.
20.
21.
22.
23.

24.

25.

26.

27.

28.
29.
30.
31.

32.

33.

Chanchamroen, S., C. Kewcharoenwong, W. Susaengrat, M. Ato, and G. Lertmemongkolchai.
2009. Human Polymorphonuclear Neutrophil Responses to Burkholderia pseudomallei in
Healthy and Diabetic Subjects. Infection and Immunity 77:456-463.
Chen, W.-T., Y.-S. Chen, S.-M. Chye, T.-R. Wu, W.-G. Hong, Y.-N. Lin, H.-T. Bair, S.-C. Yang, and
Y.-L. Chen. 2005. Seroprevalence of melioidosis in diabetic patients in Taiwan. Journal of
Microbiology Immunology and Infection 38:267-270.
Chen, Y. S., Y. S. Hsiao, H. H. Lin, C. M. Yen, S. C. Chen, and Y. L. Chen. 2006. Immunogenicity
and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA
encoding flagellin. Vaccine 24:750-758.
Cheng, A. C., and B. J. Currie. 2007. Melioidosis: Epidemiology, pathophysiology, and
management (vol 18, pg 383, 2005). Clinical Microbiology Reviews 20:533-533.
Cheng, A. C., S. P. Jacups, L. Ward, and B. J. Currie. 2008. Melioidosis and Aboriginal seasons in
northern Australia. Trans R Soc Trop Med Hyg 102 Suppl 1:S26-9.
Choy, J. L., M. Mayo, A. Janmaat, and B. J. Currie. 2000. Animal melioidosis in Australia. Acta
Trop 74:153-8.
Chua, K. L., Y. Y. Chan, and Y. H. Gan. 2003. Flagella are virulence determinants of Burkholderia
pseudomallei. Infection and Immunity 71:1622-1629.
Chuaygud, T., Tungpradabkul, S., Sirisinha, S., Chua, K. L., Utaisincharoen, P. . 2008. A
role of Burkholderia pseudomallei flagella as a virulent factor. Transactions of the Royal Society
of Tropical Medicine and 102:140-144.
Currie, B. J. 2008. Advances and remaining uncertainties in the epidemiology of Burkholderia
pseudomallei and melioidosis. Transactions of the Royal Society of Tropical Medicine and
Hygiene 102:225-227.
Currie, B. J., S. P. Jacups, A. C. Cheng, D. A. Fisher, N. M. Anstey, S. E. Huffam, and V. L. Krause.
2004. Melioidosis epidemiology and risk factors from a prospective whole-population study in
northern Australia. Tropical Medicine & International Health 9:1167-1174.
DeShazer, D., P. J. Brett, R. Carlyon, and D. E. Woods. 1997. Mutagenesis of Burkholderia
pseudomallei with Tn5-OT182: Isolation of motility mutants and molecular characterization of
the flagellin structural gene. Journal of Bacteriology 179:2116-2125.
Dickey, L. L. 2007. An infection model for examining the effects of gender and diabetic state on
proinflammatory cytokine secretion by phagocytic cells in response to infection with
Burkholderia pseudomallei. Brigham Young University, Provo.
Dorshkind, K., E. Montecino-Rodriguez, and R. A. J. Signer. 2009. The ageing immune system: is
it ever too old to become young again? Nat Rev Immunol 9:57-62.
Eberl, L. 2006. Quorum sensing in the genus Burkholderia. International Journal of Medical
Microbiology 296:103-110.
Egan, A. M., and D. L. Gordon. 1996. Burkholderia pseudomallei activates complement and is
ingested but not killed by polymorphonuclear leukocytes. Infection and Immunity 64:4952-4959.
Erskine, P. T., M. J. Knight, A. Ruaux, H. Mikolajek, N. W. F. Sang, J. Withers, R. Gill, S. P. Wood,
M. Wood, G. C. Fox, and J. B. Cooper. 2006. High resolution structure of BipD: An invasion
protein associated with the type III secretion system of Burkholderia pseudomallei. Journal of
Molecular Biology 363:125-136.
Essex-Lopresti, A. E., J. A. Boddey, R. Thomas, M. P. Smith, M. G. Hartley, T. Atkins, N. F.
Brown, C. H. Tsang, I. R. A. Peak, J. Hill, I. R. Beacham, and R. W. Titball. 2005. A type IV pilin,
PilA, contributes to adherence of Burkholderia pseudomallei and virulence in vivo. Infection and
Immunity 73:1260-1264.
Forbes-Faulkner, J. C., W. L. Townsend, and A. D. Thomas. 1992. Pseudomonas pseudomallei
infection in camels. Aust Vet J 69:148.
52

34.

35.
36.
37.

38.
39.

40.

41.

42.

43.
44.
45.
46.
47.

48.

49.
50.

Friedland, J. S., Y. Suputtamongkol, D. G. Remick, W. Chaowagul, R. M. Strieter, S. L. Kunkel, N.
J. White, and G. E. Griffin. 1992. Prolonged elevation of interleukin-8 and interleukin-6
concentrations in plasma and of leukocyte interleukin-8 messenger-RNA levels during
septicemic and localized Pseudomonas pseudomallei infection. Infection and Immunity 60:24022408.
Fujihashi, K., and H. Kiyono. 2009. Mucosal immunosenescence: new developments and
vaccines to control infectious diseases. Trends in Immunology 30:334-343.
Gauthier, Y. P., F. M. Thibault, J. C. Paucod, and D. R. Vidal. 2000. Protease production by
Burkholderia pseudomallei and virulence in mice. Acta Tropica 74:215-220.
Godoy, D., G. Randle, A. J. Simpson, D. M. Aanensen, T. L. Pitt, R. Kinoshita, and B. G. Spratt.
2003. Multilocus sequence typing and evolutionary relationships among the causative agents of
melioidosis and glanders, Burkholderia pseudomallei and Burkholdefia mallei (vol 41, pg 2068,
2003). Journal of Clinical Microbiology 41:4913-4913.
Goldberg, E., and I. Krause. 2009. Infection and type 1 diabetes mellitus - A two edged sword?
Autoimmunity Reviews 8:682-686.
Goodyear, A., L. Kellihan, H. Bielefeldt-Ohmann, R. Troyer, K. Propst, and S. Dow. 2009.
Protection from Pneumonic Infection with Burkholderia Species by Inhalational Immunotherapy.
Infection and Immunity 77:1579-1588.
Gori, A. H., K. Ahmed, G. Martinez, H. Masaki, K. Watanabe, and T. Nagatake. 1999. Mediation
of attachment of Burkholderia pseudomallei to human pharyngeal epithelial cells by the
asialoganglioside GM1-GM2 receptor complex. American Journal of Tropical Medicine and
Hygiene 61:473-475.
Haraga, A., T. E. West, M. J. Brittnacher, S. J. Skerrett, and S. I. Miller. 2008. Burkholderia
thailandensis as a Model System for the Study of the Virulence-Associated Type III Secretion
System of Burkholderia pseudomallei. Infection and Immunity 76:5402-5411.
Ho, M., T. Schollaardt, M. D. Smith, M. B. Perry, P. J. Brett, W. Chaowagul, and L. E. Bryan.
1997. Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide
antibodies. Infection and Immunity 65:3648-3653.
Inglis, T. J. J., and A. Q. Sousa. 2009. The Public Health Implications of Melioidosis. Brazilian
Journal of Infectious Diseases 13:59-66.
Jones, A. L., T. J. Beveridge, and D. E. Woods. 1996. Intracellular survival of Burkholderia
pseudomallei. Infection and Immunity 64:782-790.
Joshi, N., G. M. Caputo, M. R. Weitekamp, and A. W. Karchmer. 1999. Infections in patients
with diabetes mellitus. New England Journal of Medicine 341:1906-1912.
Ketterer, P. J., W. R. Webster, J. Shield, R. J. Arthur, P. J. Blackall, and A. D. Thomas. 1986.
Melioidosis in intensive piggeries in south eastern Queensland. Aust Vet J 63:146-9.
Knight, M. J., A. Ruaux, H. Mikolajek, P. T. Erskine, R. Gill, S. P. Wood, M. Wood, and J. B.
Cooper. 2006. Crystallization and preliminary X-ray diffraction analysis of BipD, a virulence
factor from Burkholderia pseudomallei. Acta Crystallographica Section F-Structural Biology and
Crystallization Communications 62:761-764.
Kramer, P. R., S. F. Kramer, and G. Guan. 2004. 17 beta-estradiol regulates cytokine release
through modulation of CD16 expression in monocytes and monocyte-derived macrophages.
Arthritis Rheum 50:1967-75.
Ladds, P. W., A. D. Thomas, and B. Pott. 1981. Melioidosis with acute
meningoencephalomyelitis in a horse. Aust Vet J 57:36-8.
Lazzaroni SM, B. J., Williams NL, Govan BL, Norton RE, LaBrooy JT, Ketheesan N. 2008.
Seropositivity to Burkholderia pseudomallei does not reflect the development of cell-mediated
immunity. Trans R Soc Trop Med Hyg. 102:66-70.
53

51.
52.

53.

54.
55.

56.

57.

58.
59.
60.

61.

62.

63.
64.

65.
66.

67.

Lee, M. A., and Y. Liu. 2000. Sequencing and characterization of a novel serine metalloprotease
from Burkholderia pseudomallei. FEMS Microbiol Lett 192:67-72.
Li, D.-S., G. L. Warnock, H.-J. Tu, Z. Ao, Z. He, H. Lu, and L.-J. Dai. 2009. Do immunotherapy and
beta cell replacement play a synergistic role in the treatment of type 1 diabetes? Life Sciences
85:549-556.
Ling, J. M. L., R. A. Moore, M. G. Surette, and D. E. Woods. 2006. The mviN homolog in
Burkholderia pseudomallei is essential for viability and virulence. Canadian Journal of
Microbiology 52:831-842.
Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time
quantitative PCR and the 2-DELTADELTACT method. Methods (Orlando) 25:402-408.
Maharjan, B., N. Chantratita, M. Vesaratchavest, A. Cheng, V. Wuthiekanun, W. Chierakul, W.
Chaowagul, N. P. Day, and S. J. Peacock. 2005. Recurrent melioidosis in patients in northeast
Thailand is frequently due to reinfection rather than relapse. J Clin Microbiol 43:6032-4.
Mahfouz, M. E., T. H. Grayson, D. A. B. Dance, and M. L. Gilpin. 2006. Characterization of the
mrgRS locus of the opportunistic pathogen Burkholderia pseudomallei: temperature regulates
the expression of a two-component signal transduction system. Bmc Microbiology 6.
Masoud, H., M. Ho, T. Schollaardt, and M. B. Perry. 1997. Characterization of the capsular
polysaccharide of Burkholderia (Pseudomonas) pseudomallei 304b. Journal of Bacteriology
179:5663-5669.
McDermott, R. A., M. Li, and S. K. Campbell. Incidence of type 2 diabetes in two Indigenous
Australian populations: a 6-year follow-up study. Med J Aust 192:562-5.
McMahon, M. M., Bistrian, B.R. 1995. Host defenses and susceptibility to infection in patients
with diabetes mellitus. Infections in Diabetes Mellitus 1:1-9.
Meumann, E. M., R. T. Novak, D. Gal, M. E. Kaestli, M. Mayo, J. P. Hanson, E. Spencer, M. B.
Glass, J. E. Gee, P. P. Wilkins, and B. J. Currie. 2006. Clinical evaluation of a type III secretion
system real-time PCR assay for diagnosing melioidosis. Journal of Clinical Microbiology 44:30283030.
Miyagi, K., K. Kawakami, and A. Saito. 1997. Role of reactive nitrogen and oxygen intermediates
in gamma interferon-stimulated murine macrophage bactericidal activity against Burkholderia
pseudomallei. Infect Immun 65:4108-13.
Montagna, P., S. Soldano, R. Brizzolara, B. Villaggio, P. Triolo, P. Clerico, M. Meroni, A. Sulli, B.
Seriolo, L. Molfetta, and M. Cutolo. Estrogens interfere with leflunomide modulation of
cytokine production by human activated monocytes. Annals of the New York Academy of
Sciences 1193:30-35.
Morici, L. A., J. Heang, T. Tate, P. J. Didier, and C. J. Roy. Differential susceptibility of inbred
mouse strains to Burkholderia thailandensis aerosol infection. Microbial Pathogenesis 48:9-17.
Muangsombut, V., S. Suparak, P. Pumirat, S. Damnin, P. Vattanaviboon, V. Thongboonkerd,
and S. Korbsrisate. 2008. Inactivation of Burkholderia pseudomallei bsaQ results in decreased
invasion efficiency and delayed escape of bacteria from endocytic vesicles. Archives of
Microbiology 190:623-631.
Nichols, J., and A. Cooke. 2009. Overcoming self-destruction in the pancreas. Current Opinion in
Biotechnology 20:511-515.
Nolan, C. M., H. N. Beaty, and J. D. Bagdade. 1978. Further characterization of the impaired
bactericidal function of granulocytes in patients with poorly controlled diabetes. Diabetes
27:889-94.
Novem, V., G. Shui, D. Wang, A. K. Bendt, S. H. Sim, Y. Liu, T. W. Thong, S. P. Sivalingam, E. E.
Ooi, M. R. Wenk, and G. Tan. 2009. Structural and Biological Diversity of Lipopolysaccharides

54

68.

69.

70.

71.

72.

73.
74.

75.

76.

77.

78.
79.

80.

81.

82.

from Burkholderia pseudomallei and Burkholderia thailandensis. Clinical and Vaccine
Immunology 16:1420-1428.
Panda, A., A. Arjona, E. Sapey, F. Bai, E. Fikrig, R. R. Montgomery, J. M. Lord, and A. C. Shaw.
2009. Human innate immunosenescence: causes and consequences for immunity in old age.
Trends in Immunology 30:325-333.
Pilatz, S., K. Breitbach, N. Hein, B. Fehlhaber, J. Schulze, B. Brenneke, L. Eberl, and I. Steinmetz.
2006. Identification of Burkholderia pseudomallei genes required for the intracellular life cycle
and in vivo virulence. Infection and Immunity 74:3576-3586.
Pongcharoen, S., P. R. Niumsup, and P. Butkhamcho. 2008. Comparative study of interleukin-1
beta expression by peripheral blood mononuclear cells and purified monocytes experimentally
infected with Burkholderia pseudomallei and Burkholderia thailandensis. Immunological
Investigations 37:704-713.
Pongcharoen, S., P. N. Ritvirool, D. Sanguansermsri, P. Chanchan, P. Jienmongkol, P.
Butkhamchot, P. Warnnissorn, N. Banchuin, and S. Sirisinha. 2008. Reduced interleukin-17
expression of Burkholderia pseudomallei-infected peripheral blood mononuclear cells of
diabetic patients. Asian Pacific Journal of Allergy and Immunology 26:63-69.
Qazi O, P. J., Judy BM, Whitlock GC, Kitto GB, Torres AG, Estes DM, Brown KA. 2008. Serocharacterization of lipopolysaccharide from Burkholderia thailandensis. Trans R Soc Trop Med
Hyg. 102:58-60.
Raja, N. S. 2008. Cases of melioidosis in a university teaching hospital in Malaysia. Journal of
Microbiology Immunology and Infection 41:174-179.
Reckseidler-Zenteno, S. L., R. DeVinney, and D. E. Woods. 2005. The capsular polysaccharide of
Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b
deposition. Infection and Immunity 73:1106-1115.
Reckseidler, S. L., D. DeShazer, P. A. Sokol, and D. E. Woods. 2001. Detection of bacterial
virulence genes by subtractive hybridization: Identification of capsular polysaccharide of
Burkholderia pseudomallei as a major virulence determinant. Infection and Immunity 69:34-44.
Sarkar-Tyson, M., S. J. Smither, S. V. Harding, T. P. Atkins, and R. W. Titball. 2009. Protective
efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental
melioidosis and glanders. Vaccine 27:4447-4451.
Sarkar-Tyson, M., J. E. Thwaite, S. V. Harding, S. J. Smither, P. C. F. Oyston, T. P. Atkins, and R.
W. Titball. 2007. Polysaccharides and virulence of Burkholderia pseudomallei. Journal of
Medical Microbiology 56:1005-1010.
Schweizer, H. P., and S. J. Peacock. 2008. Antimicrobial Drug-Selection Markers for Burkholderia
pseudomallei and B-mallei. Emerging Infectious Diseases 14:1689-1692.
Shalom, G., J. G. Shaw, and M. S. Thomas. 2007. In vivo expression technology identifies a type
VI secretion system locus in Burkholderia pseudomallei that is induced upon invasion of
macrophages. Microbiology 153:2689-99.
Shalom, G., J. G. Shaw, and M. S. Thomas. 2007. In vivo expression technology identifies a type
VI secretion system locus in Burkholderia pseudomallei that is induced upon invasion of
macrophages. Microbiology-Sgm 153:2689-2699.
Si, D., R. Bailie, M. Dowden, C. Kennedy, R. Cox, L. O'Donoghue, H. Liddle, R. Kwedza, C.
Connors, S. Thompson, H. Burke, A. Brown, and T. Weeramanthri. Assessing quality of diabetes
care and its variation in Aboriginal community health centres in Australia. Diabetes/Metabolism
Research and Reviews 26:464-473.
Smith, R. P., A. L. Baltch, W. J. Ritz, P. B. Michelsen, and L. H. Bopp. IFN-gamma enhances
killing of methicillin-resistant Staphylococcus aureus by human monocytes more effectively than
GM-CSF in the presence of daptomycin and other antibiotics. Cytokine 51:274-7.
55

83.
84.

85.

86.

87.

88.
89.

90.

91.

92.

93.

94.

95.

96.

97.

Song, Y., C. Xie, Y. M. Ong, Y. H. Gan, and K. L. Chua. 2005. The BpsIR quorum-sensing system of
Burkholderia pseudomallei. Journal of Bacteriology 187:785-790.
Steinmetz, I., M. Rohde, and B. Brenneke. 1995. Purification and characterization of an
exopolysaccharide of Burkholderia (Pseudomonas) pseudomallei. Infection and Immunity
63:3959-3965.
Stevens, M. P., A. Friebel, L. A. Taylor, M. W. Wood, P. J. Brown, W. D. Hardt, and E. E. Galyov.
2003. A Burkholderia pseudomallei type III secreted protein, BopE, facilitates bacterial invasion
of epithelial cells and exhibits guanine nucleotide exchange factor activity. J Bacteriol 185:49926.
Suparak, S., W. Kespichayawattana, A. Haque, A. Easton, S. Damnin, G. Lertmemongkolchai, G.
J. Bancroft, and S. Korbsrisate. 2005. Multinucleated giants cell formation and apoptosis in
infected host cells is mediated by Burkholderia pseudomallei type III secretion protein BipB.
Journal of Bacteriology 187:6556-6560.
Taweechaisupapong, S., C. Kaewpa, C. Arunyanart, P. Kanla, P. Homchampa, S. Sirisinha, T.
Proungvitaya, and S. Wongratanacheewin. 2005. Virulence of Burkholderia pseudomallei does
not correlate with biofilm formation. Microbial Pathogenesis 39:77-85.
Thomas, A. D. 1981. Prevalence of melioidosis in animals in northern Queensland. Aust Vet J
57:146-8.
Tippayawat, P., W. Saenwongsa, J. Mahawantung, D. Suwannasaen, P. Chetchotisakd, D.
Limmathurotsakul, S. J. Peacock, P. L. Felgner, H. S. Atkins, R. W. Titball, G. J. Bancroft, and G.
Lertmemongkolchai. 2009. Phenotypic and Functional Characterization of Human Memory T
Cell Responses to to Burkholderia pseudomallei. Plos Neglected Tropical Diseases 3.
Titball RW, R. P., Cuccui J, Easton A, Haque A, Atkins T, Sarkar-Tyson M, Harley V, Wren B,
Bancroft GJ. 2008. Burkholderia pseudomallei: animal models of infection. Trans R Soc Trop
Med Hyg. 102:111-116.
Tuckermann, J. P., A. Kleiman, K. G. McPherson, and H. M. Reichardt. 2005. Molecular
mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit
Rev Clin Lab Sci 42:71-104.
Tuckermann, J. P., A. Kleiman, R. Moriggl, R. Spanbroek, A. Neumann, A. Illing, B. E. Clausen,
B. Stride, I. Forster, A. J. Habenicht, H. M. Reichardt, F. Tronche, W. Schmid, and G. Schutz.
2007. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids
in contact allergy. J Clin Invest 117:1381-90.
Ulett, G. C., B. J. Currie, T. W. Clair, M. Mayo, N. Ketheesan, J. Labrooy, D. Gal, R. Norton, C. A.
Smith, J. Barnes, J. Warner, and R. G. Hirst. 2001. Burkholderia pseudomallei virulence:
definition, stability and association with clonality. Microbes and Infection 3:621-631.
Ulett, G. C., N. Ketheesan, and R. G. Hirst. 2000. Cytokine gene expression in innately
susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent
Burkholderia pseudomallei. Infection and Immunity 68:2034-2042.
Utaisincharoen, P., N. Tangthawornchaikul, W. Kespichayawattana, N. Anuntagool, P.
Chaisuriya, and S. Sirisinha. 2000. Kinetic studies of the production of nitric oxide (NO) and
tumour necrosis factor-alpha (TNF-alpha) in macrophages stimulated with Burkholderia
pseudomallei endotoxin. Clinical and Experimental Immunology 122:324-329.
Valade, E., F. M. Thibault, Y. P. Gauthier, M. Palencia, M. Y. Popoff, and D. R. Vidal. 2004. The
PmlI-PmlR quorum-sensing system in Burkholderia pseudomallei plays a key role in virulence
and modulates production of the MprA protease. Journal of Bacteriology 186:2288-2294.
van Schaik, E. J., M. Tom, and D. E. Woods. 2009. Burkholderia pseudomallei Isocitrate Lyase Is
a Persistence Factor in Pulmonary Melioidosis: Implications for the Development of Isocitrate
Lyase Inhibitors as Novel Antimicrobials. Infection and Immunity 77:4275-4283.
56

98.

99.

100.

101.
102.

103.

104.
105.
106.

107.
108.

Verreck, F. A. W., T. d. Boer, D. M. L. Langenberg, M. A. Hoeve, M. Kramer, E. Vaisberg, R.
Kastelein, A. Kolk, R. de Waal-Malefyt, and T. H. M. Ottenhoff. 2004. Human IL-23-producing
type 1 macrophages promote but IL-10-producing type 2, macrophages subvert, immunity to
(myco)bacteria. Proceedings of the National Academy of Sciences of the United States of
America 101:4560-4565.
Warawa, J., and D. E. Woods. 2005. Type III secretion system cluster 3 is required for maximal
virulence of Burkholderia pseudomallei in a hamster infection model. Fems Microbiology Letters
242:101-108.
Warawa, J. M., D. Long, R. Rosenke, D. Gardner, and F. C. Gherardini. 2009. Role for the
Burkholderia pseudomallei Capsular Polysaccharide Encoded by the wcb Operon in Acute
Disseminated Melioidosis. Infection and Immunity 77:5252-5261.
White, N. J. 2003. Melioidosis. Lancet 361:1715-1722.
Wiersinga, W. J., C. W. Wieland, M. C. Dessing, N. Chantratita, A. C. Cheng, D.
Limmathurotsakul, W. Chierakul, M. Leendertse, S. Florquin, A. F. de Vos, N. White, A. M.
Dondorp, N. P. Day, S. J. Peacock, and T. van der Poll. 2007. Toll-like receptor 2 impairs host
defense in gram-negative sepsis caused by Burkholderia pseudomallei (Melioidosis). Plos
Medicine 4:1268-1280.
Wikraiphat, C., J. Charoensap, P. Utaisincharoen, S. Wongratanacheewin, S.
Taweechaisupapong, D. E. Woods, J. G. M. Bolscher, and S. Sirisinha. 2009. Comparative in vivo
and in vitro analyses of putative virulence factors of Burkholderia pseudomallei using
lipopolysaccharide, capsule and flagellin mutants. FEMS Immunology and Medical Microbiology
56:253-259.
Wuthiekanun, V., M. D. Smith, and N. J. White. 1995. Survival of Burkholderia pseudomallei in
the absence of nutrients. Trans R Soc Trop Med Hyg 89:491.
Yang, H. M., W. Chaowagul, and P. A. Sokol. 1991. Sideropohre production by Pseudomonas
pseudomallei. Infection and Immunity 59:776-780.
Yang, H. M., C. D. Kooi, and P. A. Sokol. 1993. Ability of Pseudomonas pseudomallei
malleobactin to acquire transferrin-bound, lactoferrin-bound, and cell-derived iron. Infection
and Immunity 61:656-662.
YH, G. 2005. Interaction between Burkholderia pseudomallei and the host immune response:
sleeping with the enemy? J Infect Dis 192:1845-1850.
Zhang, L. L., Y. Wang, W. L. Picking, W. D. Picking, and R. N. De Guzman. 2006. Solution
structure of monomeric BsaL, the type III secretion needle protein of Burkholderia pseudomallei.
Journal of Molecular Biology 359:322-330.

57

